Wireless device recommended for treating people with overactive bladder
Axonics SNS has potential to save the NHS around £6,200 per patient if the device lasts more than six years
-
Researchers wanted to study the public’s views of health-related quality of life
Applications close on Wednesday 4 March 2020
-
Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine
NICE has today (4 February 2020) published the outcome of the appeal against its final draft guidance (FAD) on erenumab (also called Aimovig and made by Novartis) for preventing chronic migraine.
-
Broader types of data to be used in development of NICE guidance
An expanded evidence base could allow NICE to address evidence gaps and enhance reviews of the impact of our guidance
